ADDEX THERAPEUTICS LTD ADXN
SPONSORED ADS · ADR · CUSIP 00654J206
Swiss public company
- SectorHealth care
- IndustryPharmaceutical Preparations
- HeadquartersPlan-les-Ouates, Switzerland
- Founded2002
- Websiteaddexpharma.com
- FilingsSEC EDGAR
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $12.80.
Trends to Q1 2024
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q4 2023 | 4 |
| Q1 2024 | 2 |
Biggest buyers
| ADAR1 Capital Management, LLC | New | +390 |
Biggest sellers
| J. Stern & Co. LLP | Sold out | -107.8k |
| ARMISTICE CAPITAL, LLC | Sold out | -43.0k |
| NEA Management Company, LLC | Sold out | -9.0k |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
Dyer Timothy Mark
13D · may seek influence
no change · filed 2026-09-04
Stated purposeThe Reporting Person acquired the securities of the Issuer at founding, through the exercise of options, acquisitions through participation in private placements and in consideration for his services as Chief Executive Officer of the Issuer. The reporting person also received shares issuable upon exercise of options. The terms of the Reporting Person's employment arrangements for 2025 were set forth in the Issuer's Annual Report on Form 20-F for such period filed by the Issuer with the Securities and Exchange Commission on May 15, 2026. Except in respect of such employment arrangements as set forth therein, the Reporting Person does not have any present plans which relate to or would result in: (a) the acquisition by any person of additional securities of the Issuer, or the disposition of… Full filing |
9.0% |
Insider purchases and sales in Q1 2024
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
None reported in Q1 2024.
Holders, Q1 2024
| Manager | Shares | Change |
|---|---|---|
| ADAR1 Capital Management, LLC 0.00% of their portfolio | 390 $5.0k | New |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0.00% of their portfolio | 0 $0 | Unchanged |